Literature DB >> 6519151

Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.

P C Ho, D W Bourne, E J Triggs, V Heazlewood.   

Abstract

The pharmacokinetics of canrenone and 'total metabolites' after base hydrolysis was studied in eight young volunteers following single and multiple dose oral administration of spironolactone. The plasma levels of canrenone and 'total metabolites' were fitted to a two-compartment open model with a first-order absorption process. From our eight normal subjects studied, the harmonic mean of the distributive half-life (t1/2 alpha) of canrenone was found to be 1.66 h, and the harmonic mean of the terminal elimination half-life (t1/2 beta) to be 22.6 h. Harmonic means of the distributive and elimination half-lives of 'total metabolites' after base hydrolysis were 2.48 h and 28.8 h respectively. The accumulation ratio of canrenone was 2.53, whereas that of 'total metabolites' was 1.89. Despite the fact that spironolactone has been shown to induce hepatic metabolism of other drugs, no evidence of autoinduction was noted in the present study, as plasma levels of canrenone and 'total metabolites' were found to obey a linear two-compartment model with reproducible absorption and disposition after single and multiple doses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6519151     DOI: 10.1007/bf00549592

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Simultaneous automated determination of spironolactone metabolites in serum.

Authors:  P Neubert; K Koch
Journal:  J Pharm Sci       Date:  1977-08       Impact factor: 3.534

2.  Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.

Authors:  C G Dahlöf; P Lundborg; B A Persson; C G Regårdh
Journal:  Drug Metab Dispos       Date:  1979 Mar-Apr       Impact factor: 3.922

3.  Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.

Authors:  W Sadée; M Dagcioglu; R Schröder
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

4.  Fluorometric microassay for spironolactone and its metabolites in biological fluids.

Authors:  W Sadée; M Dagcioglu; S Riegelman
Journal:  J Pharm Sci       Date:  1972-07       Impact factor: 3.534

5.  Estimating the accumulation of drugs.

Authors:  W A Colburn
Journal:  J Pharm Sci       Date:  1983-07       Impact factor: 3.534

6.  Conversion of spironolactone to an active metabolite in target tissues: formation of 7 alpha-thiospironolactone by microsomal preparations from guinea pig liver, adrenals, kidneys, and testes.

Authors:  J H Sherry; J P O'Donnell; H D Colby
Journal:  Life Sci       Date:  1981-12-28       Impact factor: 5.037

7.  Pharmacokinetics of spironolactone in man.

Authors:  U Abshagen; H Rennekamp; G Luszpinski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-12       Impact factor: 3.000

8.  Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.

Authors:  A Karim; J Zagarella; T C Hutsell; M Dooley
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

9.  Spironolactone and canrenoate-K: relative potency at steady state.

Authors:  L Ramsay; M Asbury; J Shelton; I Harrison
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

10.  Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment.

Authors:  U Abshagen; H Rennekamp; G Luszpinski
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

View more
  3 in total

1.  Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone.

Authors:  P C Ho; D W Bourne; E J Triggs; B A Smithurst
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 2.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 3.  Aldosterone receptor antagonists: current perspectives and therapies.

Authors:  Jason L Guichard; Donald Clark; David A Calhoun; Mustafa I Ahmed
Journal:  Vasc Health Risk Manag       Date:  2013-06-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.